<p>Hims  Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 首席财务官 Oluyemi Okupe 于 5 月 18 日星期一出售了 7,950 股 Hims  Hers Health 股票。股票以平均价格 $23.64 出售，总价值为 $187,938.00。出售后，首席财务官直接持有该公司 262,954 股股票，价值 $6,216,232.56。此次交易使其持股减少了 2.93%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
<p>获取 <strong>Hims  Hers Health</strong> 的提醒：</p>
<ul>
<li>Hims  Hers 股票在第一季度业绩不佳后暴跌：GLP-1 转型是否足以推动复苏？</li>
</ul>
<p>Oluyemi Okupe 最近还进行了以下交易：</p>
<ul>
<li>4 月 20 日星期一，Oluyemi Okupe 出售了 19,645 股 Hims  Hers Health 股票。股票以平均价格 $29.96 出售，总价值为 $588,564.20。</li>
<li>4 月 16 日星期四，Oluyemi Okupe 出售了 36,922 股 Hims  Hers Health 股票。股票以平均价格 $25.90 出售，总价值为 $956,279.80。</li>
<li>4 月 17 日星期五，Oluyemi Okupe 出售了 18,005 股 Hims  Hers Health 股票。股票以平均价格 $27.83 出售，总交易额为 $501,079.15。</li>
<li>4 月 6 日星期一，Oluyemi Okupe 出售了 3,975 股 Hims  Hers Health 股票。股票以平均价格 $19.98 出售，总交易额为 $79,420.50。</li>
<li>3 月 20 日星期五，Oluyemi Okupe 出售了 9,217 股 Hims  Hers Health 股票。股票以平均价格 $23.77 出售，总交易额为 $219,088.09。</li>
</ul>
<h2>Hims  Hers Health 价格表现</h2>
<p>HIMS 股票在周二的午盘交易中上涨 $0.18，达到 $22.47。该公司交易了 27,295,336 股，相较于其平均交易量 28,940,582 股。该公司的 50 日移动平均价格为 $24.05，200 日移动平均价格为 $28.43。该公司的市值为 51.2 亿美元，市盈率为 -249.61，PEG 比率为 39.32，贝塔值为 2.43。Hims  Hers Health, Inc. 的 12 个月低点为 $13.74，12 个月高点为 $70.43。该公司的债务与股本比率为 2.18，速动比率为 1.56，流动比率为 1.69。</p>
<ul>
<li>Hims  Hers 财报预览：诺和诺德的转变将 GLP-1 战略置于焦点</li>
</ul>
<p>Hims  Hers Health (NYSE:HIMS - 获取免费报告) 最近于 5 月 11 日星期一发布了季度财报。公司报告本季度每股收益为 ($0.40)，低于分析师一致预期的 $0.04，差距为 ($0.44)。本季度公司收入为 $608.10 百万，而分析师预期为 $616.84 百万。Hims  Hers Health 的净利润率为 -0.56%，股本回报率为 6.10%。与去年同期相比，Hims  Hers Health 的收入增长了 3.8%。在去年同期，该公司每股收益为 $0.20。平均而言，卖方分析师预计 Hims  Hers Health, Inc. 本年度每股收益将为 0.04。</p>
<h2>影响 Hims  Hers Health 的关键故事</h2>
<p>以下是本周影响 Hims  Hers Health 的关键新闻：</p>
<ul>
<li>积极情绪：更大规模的融资使 Hims  Hers 拥有更多资本，以追求国际扩张、收购计划和技术投资，而无需使用过多的运营现金。Hims  Hers Health, Inc. 定价增发 3.5 亿美元可转换高级票据，以支持国际扩张并加速 AI 驱动的平台投资。</li>
<li>中性情绪：美国银行将 Hims  Hers 的目标价从 $30 下调至 $28，并维持中性评级，尽管目标价仍高于近期股价，显示出更谨慎的预期。Benzinga 报道美国银行下调目标价。</li>
<li>消极情绪：投资者担心可转换票据可能会稀释股东权益，这导致融资公告后股票下滑。为什么 Hims  Hers 股票今天下跌。</li>
<li>消极情绪：公司的最新财报电话会议和最近的第一季度业绩也使情绪保持疲软，市场仍关注上个季度的业绩不佳和低于预期的收入。Hims  Hers Health, Inc. 宣布拟发行可转换高级票据，以支持国际扩张并加速 AI 驱动的平台投资。</li>
</ul>
<h2>对 Hims  Hers Health 的对冲基金看法</h2>
<ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
<p>几家机构投资者和对冲基金最近增加或减少了在该公司的持股。瑞银资产管理公司（UBS AM）在第一季度将其在 Hims  Hers Health 的持股增加了 23.1%。瑞银资产管理公司现在拥有 418,699 股该公司的股票，价值 $12,373,000，此前在此期间又购买了 78,543 股。Geneos Wealth Management Inc. 在第一季度获得了 Hims  Hers Health 的新头寸，价值 $30,000。EverSource Wealth Advisors LLC 在第二季度将其在 Hims  Hers Health 的持股增加了 273.7%。EverSource Wealth Advisors LLC 现在拥有 938 股该公司的股票，价值 $47,000，此前在上个季度又购买了 687 股。Amundi 在第二季度将其在 Hims  Hers Health 的持股增加了 5.3%。Amundi 现在拥有 10,296 股该公司的股票，价值 $489,000，此前在此期间又购买了 522 股。最后，加利福尼亚公共雇员退休系统在第二季度将其在 Hims  Hers Health 的持股增加了 9.5%。加利福尼亚公共雇员退休系统现在拥有 338,620 股该公司的股票，价值 $16,880,000，此前在此期间又购买了 29,471 股。63.52% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位研究分析师最近对该公司发表了看法。Evercore 在 2 月 24 日的研究报告中对 Hims &amp; Hers Health 设定了 24.00 美元的目标价。Weiss Ratings 在 5 月 12 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有 (c)” 下调至 “卖出 (d)”。Wall Street Zen 在 5 月 9 日的报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “卖出”。Barclays 在 3 月 11 日的研究报告中将 Hims &amp; Hers Health 的目标价从 25.00 美元上调至 29.00 美元，并给予该股票 “增持” 评级。最后，Truist Financial 在 2 月 24 日的研究报告中重申了 “持有” 评级，并将 Hims &amp; Hers Health 的目标价下调至 18.00 美元（低于 37.00 美元）。四位分析师对该股票给予了买入评级，十一位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 29.37 美元。</p>
<p><strong>查看我们关于 Hims &amp; Hers Health 的最新研究报告</strong></p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务。该公司以 Hims &amp; Hers 品牌运营，提供一个综合的数字体验，将用户与持牌医疗提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康问题。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
<p>该公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入探讨 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模 AI 驱动的突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

医疗业 ETF - Vanguard

标普医疗保健服务 ETF - SPDR

美国医疗保健供应商 ETF - iShares

2 倍做多 HIMS ETF - Defiance

HIMY

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

<p>Hims & Hers Health 首席财务官 Oluyemi Okupe 以每股 23.64 美元的价格出售了 7,950 股，总计 187,938 美元，减少了 2.93% 的持股。出售后，他持有 262,954 股，价值约 622 万美元。此次交易是预先安排的交易计划的一部分，并已向美国证券交易委员会（SEC）披露。该公司的股票经历了波动，最近的收益未达到预期，市值为 51.2 亿美元</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 7,950 shares of Hims &amp; Hers Health stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. The trade was a 2.93% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p>
<div class="lb-trans"><p>Hims  Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 首席财务官 Oluyemi Okupe 于 5 月 18 日星期一出售了 7,950 股 Hims  Hers Health 股票。股票以平均价格 $23.64 出售，总价值为 $187,938.00。出售后，首席财务官直接持有该公司 262,954 股股票，价值 $6,216,232.56。此次交易使其持股减少了 2.93%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims  Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 股票在第一季度业绩不佳后暴跌：GLP-1 转型是否足以推动复苏？</li>
</ul>
</div><p>Oluyemi Okupe also recently made the following trade(s):</p>
<div class="lb-trans"><p>Oluyemi Okupe 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.</li>
<li>On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.</li>
<li>On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.</li>
<li>On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $19.98, for a total transaction of $79,420.50.</li>
<li>On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09.</li>
</ul>
<div class="lb-trans"><ul>
<li>4 月 20 日星期一，Oluyemi Okupe 出售了 19,645 股 Hims  Hers Health 股票。股票以平均价格 $29.96 出售，总价值为 $588,564.20。</li>
<li>4 月 16 日星期四，Oluyemi Okupe 出售了 36,922 股 Hims  Hers Health 股票。股票以平均价格 $25.90 出售，总价值为 $956,279.80。</li>
<li>4 月 17 日星期五，Oluyemi Okupe 出售了 18,005 股 Hims  Hers Health 股票。股票以平均价格 $27.83 出售，总交易额为 $501,079.15。</li>
<li>4 月 6 日星期一，Oluyemi Okupe 出售了 3,975 股 Hims  Hers Health 股票。股票以平均价格 $19.98 出售，总交易额为 $79,420.50。</li>
<li>3 月 20 日星期五，Oluyemi Okupe 出售了 9,217 股 Hims  Hers Health 股票。股票以平均价格 $23.77 出售，总交易额为 $219,088.09。</li>
</ul>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims  Hers Health 价格表现</h2>
</div><p>Shares of HIMS stock traded up $0.18 during midday trading on Tuesday, reaching $22.47. 27,295,336 shares of the company were exchanged, compared to its average volume of 28,940,582. The company's 50 day moving average price is $24.05 and its two-hundred day moving average price is $28.43. The company has a market cap of $5.12 billion, a P/E ratio of -249.61, a PEG ratio of 39.32 and a beta of 2.43. Hims &amp; Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.</p>
<div class="lb-trans"><p>HIMS 股票在周二的午盘交易中上涨 $0.18，达到 $22.47。该公司交易了 27,295,336 股，相较于其平均交易量 28,940,582 股。该公司的 50 日移动平均价格为 $24.05，200 日移动平均价格为 $28.43。该公司的市值为 51.2 亿美元，市盈率为 -249.61，PEG 比率为 39.32，贝塔值为 2.43。Hims  Hers Health, Inc. 的 12 个月低点为 $13.74，12 个月高点为 $70.43。该公司的债务与股本比率为 2.18，速动比率为 1.56，流动比率为 1.69。</p>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 财报预览：诺和诺德的转变将 GLP-1 战略置于焦点</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims &amp; Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims &amp; Hers Health's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.20 EPS. On average, sell-side analysts expect that Hims &amp; Hers Health, Inc. will post 0.04 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health (NYSE:HIMS - 获取免费报告) 最近于 5 月 11 日星期一发布了季度财报。公司报告本季度每股收益为 ($0.40)，低于分析师一致预期的 $0.04，差距为 ($0.44)。本季度公司收入为 $608.10 百万，而分析师预期为 $616.84 百万。Hims  Hers Health 的净利润率为 -0.56%，股本回报率为 6.10%。与去年同期相比，Hims  Hers Health 的收入增长了 3.8%。在去年同期，该公司每股收益为 $0.20。平均而言，卖方分析师预计 Hims  Hers Health, Inc. 本年度每股收益将为 0.04。</p>
</div><h2>Key Stories Impacting Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>影响 Hims  Hers Health 的关键故事</h2>
</div><p>Here are the key news stories impacting Hims &amp; Hers Health this week:</p>
<div class="lb-trans"><p>以下是本周影响 Hims  Hers Health 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: The larger financing gives Hims &amp; Hers more capital to pursue international expansion, acquisition plans, and technology investment without using as much operating cash. Hims &amp; Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</li>
<li>Neutral Sentiment: Bank of America lowered its price target on Hims &amp; Hers to $28 from $30 and kept a neutral rating, signaling more cautious expectations even though the target still sits above the recent share price. Benzinga report on Bank of America price target cut</li>
<li>Negative Sentiment: Investors are worried the convertible notes could dilute shareholders later, which has contributed to the stock sliding after the financing announcement. Why Hims &amp; Hers Stock Is Falling Today</li>
<li>Negative Sentiment: The company’s latest earnings call and recent Q1 results have also kept sentiment weak, with the market still focused on the prior quarter’s earnings miss and softer-than-expected revenue. Hims &amp; Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：更大规模的融资使 Hims  Hers 拥有更多资本，以追求国际扩张、收购计划和技术投资，而无需使用过多的运营现金。Hims  Hers Health, Inc. 定价增发 3.5 亿美元可转换高级票据，以支持国际扩张并加速 AI 驱动的平台投资。</li>
<li>中性情绪：美国银行将 Hims  Hers 的目标价从 $30 下调至 $28，并维持中性评级，尽管目标价仍高于近期股价，显示出更谨慎的预期。Benzinga 报道美国银行下调目标价。</li>
<li>消极情绪：投资者担心可转换票据可能会稀释股东权益，这导致融资公告后股票下滑。为什么 Hims  Hers 股票今天下跌。</li>
<li>消极情绪：公司的最新财报电话会议和最近的第一季度业绩也使情绪保持疲软，市场仍关注上个季度的业绩不佳和低于预期的收入。Hims  Hers Health, Inc. 宣布拟发行可转换高级票据，以支持国际扩张并加速 AI 驱动的平台投资。</li>
</ul>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>对 Hims  Hers Health 的对冲基金看法</h2>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Hims &amp; Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims &amp; Hers Health during the first quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its stake in Hims &amp; Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock worth $47,000 after acquiring an additional 687 shares in the last quarter. Amundi boosted its position in Hims &amp; Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company's stock worth $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System boosted its position in Hims &amp; Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company's stock worth $16,880,000 after acquiring an additional 29,471 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了在该公司的持股。瑞银资产管理公司（UBS AM）在第一季度将其在 Hims  Hers Health 的持股增加了 23.1%。瑞银资产管理公司现在拥有 418,699 股该公司的股票，价值 $12,373,000，此前在此期间又购买了 78,543 股。Geneos Wealth Management Inc. 在第一季度获得了 Hims  Hers Health 的新头寸，价值 $30,000。EverSource Wealth Advisors LLC 在第二季度将其在 Hims  Hers Health 的持股增加了 273.7%。EverSource Wealth Advisors LLC 现在拥有 938 股该公司的股票，价值 $47,000，此前在上个季度又购买了 687 股。Amundi 在第二季度将其在 Hims  Hers Health 的持股增加了 5.3%。Amundi 现在拥有 10,296 股该公司的股票，价值 $489,000，此前在此期间又购买了 522 股。最后，加利福尼亚公共雇员退休系统在第二季度将其在 Hims  Hers Health 的持股增加了 9.5%。加利福尼亚公共雇员退休系统现在拥有 338,620 股该公司的股票，价值 $16,880,000，此前在此期间又购买了 29,471 股。63.52% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts recently weighed in on the company. Evercore set a $24.00 target price on Hims &amp; Hers Health in a research note on Tuesday, February 24th. Weiss Ratings lowered Hims &amp; Hers Health from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research note on Tuesday, May 12th. Wall Street Zen cut Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, May 9th. Barclays boosted their target price on Hims &amp; Hers Health from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, March 11th. Finally, Truist Financial reiterated a &#34;hold&#34; rating and issued a $18.00 price target (down from $37.00) on shares of Hims &amp; Hers Health in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and an average price target of $29.37.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了看法。Evercore 在 2 月 24 日的研究报告中对 Hims &amp; Hers Health 设定了 24.00 美元的目标价。Weiss Ratings 在 5 月 12 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有 (c)” 下调至 “卖出 (d)”。Wall Street Zen 在 5 月 9 日的报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “卖出”。Barclays 在 3 月 11 日的研究报告中将 Hims &amp; Hers Health 的目标价从 25.00 美元上调至 29.00 美元，并给予该股票 “增持” 评级。最后，Truist Financial 在 2 月 24 日的研究报告中重申了 “持有” 评级，并将 Hims &amp; Hers Health 的目标价下调至 18.00 美元（低于 37.00 美元）。四位分析师对该股票给予了买入评级，十一位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 29.37 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Hims &amp; Hers Health 的最新研究报告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务。该公司以 Hims &amp; Hers 品牌运营，提供一个综合的数字体验，将用户与持牌医疗提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康问题。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>该公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入探讨 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模 AI 驱动的突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

礼来

诺和诺德公司

美国银行

瑞银集团

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

内部人士出售：Hims & Hers Health（NYSE:HIMS）的首席财务官出售了 7,950 股股票